US FDA Commissioner Scott Gottlieb’s choice of Flatiron Health Inc. executive Amy Abernethy as his principal deputy commissioner to success a retiring Rachel Sherman offers one potential succession plan, should he decide to eventually leave the agency.
In Abernethy, Gottlieb brings to FDA an individual whose background neatly overlaps with much of the agency’s leadership over the past two decades
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?